Syros Pharmaceuticals (NASDAQ: SYRS) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.
Volatility & Risk
Syros Pharmaceuticals has a beta of -3.33, indicating that its stock price is 433% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.
Insider and Institutional Ownership
59.8% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.6% of MediWound shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Syros Pharmaceuticals and MediWound, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals presently has a consensus target price of $26.14, indicating a potential upside of 102.71%. MediWound has a consensus target price of $10.00, indicating a potential upside of 100.00%. Given Syros Pharmaceuticals’ higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than MediWound.
This table compares Syros Pharmaceuticals and MediWound’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Syros Pharmaceuticals and MediWound’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$320,000.00||1,054.97||-$47.74 million||($2.13)||-6.05|
|MediWound||$1.56 million||84.46||-$18.88 million||($0.75)||-6.67|
MediWound has higher revenue and earnings than Syros Pharmaceuticals. MediWound is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syros Pharmaceuticals beats MediWound on 7 of the 13 factors compared between the two stocks.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
What are top analysts saying about Syros Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syros Pharmaceuticals Inc. and related companies.